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Abstract
Salmonella Typhi, first isolated in 1884, results in infection of the intestines and can end in death and disability. Due to
serious adverse events post vaccination, whole cell killed vaccines have been replaced with new generation vaccines. The
efficacy of Vi polysaccharide (ViPS) vaccine, a new generation, single-dose intramuscular typhoid vaccine was assessed in
Nepal in 1987. However, despite the availability of ViPS vaccine for more than 25 years, Nepal has one of the highest
incidence of typhoid fever. Therefore we collected information from hospitals in the Kathmandu Valley from over the past
five years. There were 9901 enteric fever cases between January 2008 and July 2012. 1,881 of these were confirmed typhoid
cases from five hospitals in the Kathmandu district. Approximately 70% of the cases involved children under 15 years old.
1281 cases were confirmed as S. Paratyphi. Vaccines should be prioritized for control of typhoid in conjunction with
improved water and sanitation conditions in Nepal and in endemic countries of Asia and Africa.
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Introduction
It has been almost 150 years since Eberth first identified
Salmonella Typhi (S. Typhi) for the first time; one of the very first
bacteria to be isolated at the time [1]. In spite of advances in
preventive medicine, humans continue to suffer from typhoid and
paratyphoid fever. The symptoms of typhoid fever range from very
mild cases of fever treated in outpatient clinics to severe forms that
result in intestinal perforation and hospitalization [2]. The current
global burden estimates indicate that more than 90% of typhoid
fever cases occur in countries in South and South East Asia [3].
Yet, the epidemiology and burden of typhoid fever are still not well
understood [4].
Typhoid fever presents challenges that range across its
diagnosis, treatment and prevention [6]. The most effective
interventions are improvements in water and sanitation, which
have resulted in the reduction of typhoid fever incidence in
developed nations where typhoid fever was once a major cause of
death [5]. Developments in water and sanitation in these settings
occurred in parallel to improvements in other areas, such as health
education and economic advancements. Similar methods of
control and eradication of the disease in many countries of Asia
demand considerable long-term socio-behavioral and economic
progress and resources which are scarce in these countries [6].
Thus, an interim preventive measure such as vaccination is critical
in these settings. There is evidence from around the world that the
disease has been successfully controlled through vaccination and
infrastructure development [7,8]. Yet, the use of available and
effective vaccines has not received the attention and support
needed for controlling typhoid fever in low and middle income
countries. Moreover, the growing rate of multi-drug resistant
strains of S. Typhi in such settings has resulted in the increased
cost of treatment and the difficulty in managing the severity of
symptoms [2]. There are currently two licensed vaccines for
typhoid, Ty21a and Vi polysaccharide vaccine. Ty21a is an oral
live attenuated vaccine available in two formulations (enteric
coated capsule and a liquid formulation). Three doses of Ty21a in
enteric-coated capsules conferred 67% efficacy over three years of
follow-up and 62% protection over seven years of follow-up given
on an every other day schedule [9]. Currently only the enteric-
coated capsule formulation is manufactured. Ty21a is not WHO
prequalified- limiting its use through United Nations procurement
system such as UNICEF, the major donor of vaccines in
developing countries.
Twenty five years ago The New England Journal of Medicine
published the efficacy results of a clinical trial conducted in Nepal
using the Vi polysaccharide (ViPS) vaccine, one of the two licensed
typhoid vaccines [10]. ViPS vaccine is single dose and can be
stored at +2 to +8 degrees Celsius. The ViPS vaccine from one
manufacturer is WHO prequalified and hence could be purchased
in countries where vaccine supply is supported by UNICEF [11].
The vaccine has been used effectively in successful programs in a
number of developing countries [12,13] as well as in travel clinics
in wealthy and developed nations. In spite of the evidence for
effectiveness of Vi polysaccharide vaccine, the vaccine has not
been used routinely in Nepal, a country with one of the highest
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rates of endemic typhoid globally. Despite the absence of robust
surveillance data, there are reports of significant typhoid fever in
the country [14].
Here, we present data from hospitals in the Kathmandu
districts, one of the three in the valley, demonstrating higher
numbers of blood culture-confirmed typhoid fever cases. Our data
should elicit joint efforts from national and international organi-
zations to control typhoid fever using existing vaccines in
conjunction with other preventive efforts to save significant health,
social and economic costs to the population in Nepal, who
contributed to the knowledge of typhoid vaccines more than two
decades ago. The use of typhoid vaccines is an important example
of obstacles and challenges faced before a licensed and effective
vaccine is made available to the people who need it the most [15].
Methods
This 5-year retrospective hospital based data report is part of an
ongoing study in Nepal. This study examines the effectiveness of
the ViPS vaccine and its feasibility in public health programs as
part of advocacy efforts aimed at using existing vaccines for the
control of typhoid fever in Nepal. Data from blood culture
confirmed cases of typhoid fever were collected from hospitals
providing inpatient and outpatient services in the Kathmandu
District, Nepal. Out of 37 hospitals, 11 hospitals provided data on
enteric fever. The remaining hospitals did not have either
laboratory facilities for establishing proper blood culture confir-
mation or a regular information recording system for fever cases.
Surveillance staff visited the hospitals with a support letter from
the Child Health Division of the Ministry of Health and
Population and extracted 2008–2012 data from outpatients and
laboratory log books on: all fever cases reported, total blood
culture assessments performed on fever cases, total blood culture
positives, total enteric fever cases, and total typhoid cases
identified.
Data was available from hospitals where records of patients
were maintained. Where possible, we also collected information on
the age of the cases presenting to these hospitals. The age
categories of cases were divided into less than 5 years, 5–15 years
and more than 15 years. We also collected data, where available,
for each month of the year since 2008. We collected summary data
from each facility and did not collect information on patient
identification. Data was entered in Microsoft excel and analyzed in
STATA version 11.1.
Ethical considerations
The study was approved by Department of Child Health,
Ministry of Health and Population, government of Nepal. There
was no direct contact of the study staff with the patients and data
was collected retrospectively and information collected from the
hospitals did not contain any identifiers of the patients. A written
or verbal informed consent was waived by Ministry of Health and
Population.
Results
In the last five years, 30,586 febrile cases presented to at least
five hospitals in Kathmandu districts (Table 1). A total of 9,901
blood culture proven enteric fever cases was recorded in the 11
hospitals in the Valley (Table 2). The annual number of cases
ranged from a minimum of 947 in 2008 to a maximum of 3010 in
2011. Janamaitri Hospital reported the majority of cases, with
3,463 (35%) since 2008 (Table 2). There were 1881 cases of blood
culture confirmed typhoid cases reported from five hospitals
during the same time period. There is more than threefold
increase in typhoid fever cases with 165 cases in 2008 to 770 cases
in 2011 (Table 3). While typhoid fever is present throughout the
year, the majority of cases are clustered around the summer
months, from March to July. Among 3,857 cases for which the
patient age was available, 456 (12%), 1,155 (30%), 2,246 (58%)
cases were from younger than five years, between five and equal to
fifteen years and older than fifteen years, respectively (Table 4).
Discussion
The data from the reporting hospitals clearly indicates that
enteric fever is a common infectious disease affecting all age
groups in Kathmandu Valley and Nepal, though adolescents and
adults are at the greatest risk. Typhoid and Paratyphoid fever are
significant infectious diseases in the population in the valley. In the
hospitals where information on fever and blood culture were
available, 4% to 8% of patients presenting with fever were typhoid
and 2% to 4% were paratyphoid fever. These numbers are
underestimates considering the sensitivity of blood culture
technique. In addition we were unable to collect uniform
information from all of the 37 hospitals that cater to infectious
diseases in the valley.
The population density in Kathmandu Valley has increased due
to migration from rural Nepal. This has developed a pressure on
water and hygiene infrastructure, resulting in compromised
conditions and the spread of infectious diseases [16]. Retrospective
data from various sources suggest that typhoid fever peaked in the
valley due to the civil unrest occurring outside of the valley in
2001, which led to a large, susceptible population moving into the
valley [17]. Other studies from the Kathmandu Valley have
reported high rates of first line anti-microbial resistance to S.
Typhi [14,18]. Antimicrobial resistance not only adds to the cost
Table 1. Distribution of enteric fever by year comparing with overall fever cases.
S.No. Description 2008 2009 2010 2011 2012
1 Total Number presented with fever 4474 5762 7303 9466 3581
2 Total number presented with fever and blood culture done 3967 89%* 4849 84% 6529 89% 8562 90% 3190 89%
3 Total number presented with fever, blood culture done and positive growth
(Typhi and paratyphi)
259 6% 382 7% 1052 14% 1091 12% 149 4%
4 Total number presented with fever, blood culture done and S. Typhi 165 4% 237 4% 515 7% 757 8% 67 2%
5 Total number presented with fever blood culture done and S. Paratyphi 94 2% 177 3% 569 8% 340 4% 106 3%
Note: data comes from four Hospitals – (AH, HAMS, KMC, KMH).
*percentages are based on number of febrile patients presenting to the hospitals.
doi:10.1371/journal.pone.0077974.t001
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and difficulty of treatment, but also prolongs the duration of
treatment and may result in unwanted complications such as gut
perforation [19]. Despite the emergence of drug resistance,
availability of antimicrobials has markedly reduced typhoid fever
related mortality, a major initiator for government supported
efforts for setting priorities for the control of diseases. We were
unable to capture information on typhoid mortality due to a lack
of typhoid specific mortality surveillance.
Vaccination against typhoid fever alone is not sufficient for the
full control of the disease [7]. Instead, typhoid fever control
demands a comprehensive strategy that includes prevention of the
disease through hand washing, maintaining personal and envi-
ronmental hygiene, adequate sewage treatment and availability of
safe and clean drinking water to reduce problems of water-borne
infections and the spread of enteric fever. In addition, as the world
has witnessed a decline in mortality due to availability of
antimicrobials, access to timely and appropriate clinical care also
helps in reducing complication rates due to typhoid and the costs
related to typhoid fever morbidity. The cost of the ViPS vaccine (9
USD per dose), that it can only be given to older than 2 years
population, challenges of delivery in routine public health
programs; and the widespread availability and use of antibiotics
are the reasons why government policy has not been developed for
typhoid vaccination. Moreover, long-term, infrastructure devel-
opment strategies are necessary for curbing the spread of diseases,
as well as for maintaining the general health of the population.
The data on the effectiveness of ViPS vaccine provides a strong
rationale for its use among other strategies in meeting public
health prevention needs for controlling typhoid fever and is
relevant for the control of disease in the Kathmandu Valley.
It is quite poignant and ironic that, while the ViPS vaccine was
tested and licensed based on data from Nepal in 1987, the country
has not had the opportunity to use the vaccine in its immunization
program [10]. Unfortunately, the general public has not been well
informed about the use of the vaccine for preventing typhoid fever.
In addition, the cost of the locally available vaccine is prohibitively
expensive for most of the Nepali population. To address this issue,
a pilot typhoid vaccination project was conducted in the
Kathmandu Valley between 2010 and 2011. The results show a
high population demand for the prevention of the disease through
the use of vaccines. Following the pilot typhoid vaccination
project, there has been increased interest in and commitment from
the Ministry of Health and Population and District Public Health
Offices for introducing the ViPS vaccine in high risk populations.
Government officials closely follow World Health Organization
(WHO) recommendations for the use of vaccines and adhere to its
procurement guidelines, that is, pre-qualification standards for the
use and purchase of vaccines. The existing WHO pre-qualified
ViPS vaccine is presently too expensive for developing country
governments with their existing health budget. However, typhoid
fever is one of the priority diseases for the Global Alliance for
Vaccines and Immunization (GAVI), which, in its meeting in
September 2011, committed its support for conjugate typhoid
fever vaccines. A conjugate vaccine has an increased duration of
efficacy and may be used for children under two years old. There
are conjugate typhoid fever vaccines in the pipeline, two of them
are licensed for use in India. The WHO-prequalification of these
vaccines is still a few years away. Considering the burden of
typhoid fever in the Kathmandu Valley and in other parts of
South Asia, it is imperative to consider ways to support the use of
existing vaccines. Unquestionably, local public health leadership
Table 2. Annual distribution of enteric fever in Kathmandu,
Nepal.
2008 2009 2010 2011 2012* Total
Tribhuvan University Teaching
Hospital
161 364 80 70 35 710
STIDH 204 165 284 189 75 917
IF Children Hospital 240 228 53 129 73 723
Janamaitri Hospital 0 809 934 1293 427 3463
Army Hospital 125 168 322 269 129 1013
Kathmandu Model Hospital 50 175 690 782 20 1717
Kathmandu Medical College 46 38 37 36 24 181
HAMS 38 33 35 33 0 139
OM Hospital 4 63 193 32 43 331
Nepal Police Hospital 64 87 120 98 70 439
Bir Hospital 19 73 59 79 38 268
Total 947 2203 2807 3010 934 9901
*data for full year of 2012 was not available at the time of data collection.
doi:10.1371/journal.pone.0077974.t002
Table 3. Annual distribution of typhoid fever cases by
hospitals in Kathmandu Valley, Nepal.
2008 2009 2010 2011 2012* Total
Army Hospital 72 82 122 105 30 411
Kathmandu Model
Hospital
35 105 345 625 13 1123
Kathmandu Medical
College
40 33 33 11 24 141
HAMS 18 17 15 16 0 66
OM Hospital 0 31 81 13 15 140
Total 165 268 596 770 82 1881
*Data for 2012 is until October.
doi:10.1371/journal.pone.0077974.t003
Table 4. Age distribution of enteric fever cases annually in
Kathmandu Valley, Nepal.
Total Enteric
fever cases ,5 years 5–15 years 15 years
N % n % n %
2008 631 105 17 258 41 268 42
2009 1328 142 11 315 24 871 66
2010 746 81 11 259 35 406 54
2011 805 77 10 220 27 508 63
2012 347 51 15 103 30 193 56
Total 3857 456 1155 2246
Note: Hospitals in above data: TH, IFCH, KMC, HHC, OH, and NPH.
TH- Tribhuvan University Teaching Hospital.
IFCH- International Friendship’s Children Hospital.
KMC- Kathmandu Medical College.
HHC- Helping Hands Community Hospital.
OH- Om Hospital.
NPH- Nepal Police Hospital.
AH- Army Hospital.
HAMS- Hospital for Advanced Medicine and Surgery.
doi:10.1371/journal.pone.0077974.t004
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should play a vital role in addressing the typhoid control agenda,
but international experts and agencies have a strong influence in
ensuring access and support of the use of existing typhoid vaccines
in countries such as Nepal [20]. Access is a key word for which
international agencies need to assume accountability in order to
address the unmet public health needs of lower income
communities that continue to suffer from typhoid in spite of
having hosted trials that resulted in the licensure and use of such
vaccines in wealthy populations who can afford it.
Limitation
The data presented is hospital-based and thus may not
represent the full picture of the distribution and rates of typhoid
fever in the Valley and Nepal. We were also unable to collect
information from all hospitals of Kathmandu district, limiting the
estimation of typhoid fever burden. The inconsistency of
information collection in these hospitals limited our ability to
compare data between hospitals and calculate proportion for
different indicators. Two hospitals from the list of hospitals that
provided us information on S. Typhi isolation rates had
significantly higher numbers compared to other hospitals. It is
likely that many of cases captured in the hospitals do not live in
Kathmandu valley.
Our data also does not consider blood culture sensitivity.
However, the cases of typhoid fever presented here are likely only
the tip of the iceberg with the actual incidence being possibly
much higher. There are other studies from the Kathmandu Valley
and from other parts of Nepal which indicate the pervasiveness of
typhoid fever in the country [14]. Data for the later quarter of
2012 was not available at the time this manuscript was written.
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